Otto Phanstiel

USPTO Granted Patents = 33 (Patent Applications = 7)

CIPO Patents = 3 (Patent Applications = 2)

EPO Patents = 1 (Patent Applications = 3)

Average Co-Inventor Count = 2.1

ph-index = 5

Forward Citations = 79(Granted Patents)

Company Filing History:

21 out of 1,310

University of Central Florida Research Foundation Inc

Institut National De La Sante Et De La Recherche Medicale

patents

4. 2 out of 88

Sanford Burnham Prebys Medical Discovery Institute

patents

5. 1 out of 1

Friedrich Alexander University

patent

where one patent can have more than one assignee

Years Active: 2006-2025

Loading Chart...

33 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12365659 - Non-polyamine based polyamine transport inhibitors and their use in the treatment of human cancers (2025-07-22),

2. 12202807 - Methods for the synthesis of activated ethylfumarates and their use as intermediates (2025-01-21),

3. 12049453 - Formation of N-protected 3,6-bis-(4-aminobutyl)-2,5-diketopiperazine through a cyclic alpha-N-protected amino ester (2024-07-30),

4. 11905268 - Anthranilic acid derivatives and their use in the treatment of human cancers (2024-02-20),

5. 11820726 - Motuporamine derivatives as antimicrobial agents and antibiotic enhancers against resistant gram-negative bacteria (2023-11-21),

6. 11479535 - Methods for the synthesis of activated ethylfumarates and their use as intermediates (2022-10-25),

7. 11345668 - Formation of N-protected 3,6-bis-(4-aminobutyl)-2,5-diketopiperazine through a cyclic α-N-protected amino ester (2022-05-31),

8. 10870628 - Formation of N-protected 3,6-bis-(4-aminobutyl)-2,5-diketopiperazine through a cyclic α-N-protected amino ester (2020-12-22),

9. 10858325 - Methods for the synthesis of activated ethylfumarates and their use as intermediates (2020-12-08),

10. 10710957 - Motuporamine derivatives as antimicrobial agents and antibiotic enhancers against resistant gram-negative bacteria (2020-07-14),

11. 10577331 - Formation of N-protected 3,6-bis-(4-aminobutyl)-2,5-diketopiperazine through a cyclic alpha-N-protected amino ester intermediate (2020-03-03),

12. RE47750 - Anti-metastatic agents predicated upon polyamine macrocylic conjugates (2019-12-02),

13. 10071969 - Methods for the synthesis of activated ethylfumarates and their use as intermediates (2018-09-11),

14. 9944609 - Formation of N-protected bis-3,6-(4-aminobutyl)-2, 5-diketopiperazine through a cyclic alpha-N-protected amino ester (2018-04-17),

15. 9926260 - Polyamine transport selective therapeutic agents with enhanced stability (2018-03-27),

Title: The Innovative Journey of Otto Phanstiel

Introduction

Otto Phanstiel, a prolific inventor based in Oviedo, Florida, has made significant contributions to the field of chemical synthesis, holding an impressive total of 32 patents. His innovative work focuses on the development of methods for synthesizing activated fumarate intermediates and aminoalkyl-diketopiperazines. This article will explore his latest patents, career highlights, and collaborations with other individuals in the industry.

Latest Patents

Among Otto Phanstiel's latest patents are two noteworthy inventions. The first patent details methods for the synthesis of activated ethylfumarates and their use as intermediates. This invention describes improved methods for synthesizing activated fumarate esters derived from various activating groups such as 4-nitrophenyl and diphenylphosphoryl azide. The embodiment illustrates the synthesis in order to improve yields and reactor throughput, focusing on the synthesis of substituted aminoalkyl-diketopiperazines from unisolated intermediates.

The second recent patent outlines the formation of N-protected 3,6-bis-(4-aminobutyl)-2,5-diketopiperazine through a cyclic alpha-N-protected amino ester. This method includes utilizing a cyclic α-N protected active amino ester and adding it to a mixture with an amine catalyst in an organic solvent, demonstrating Otto's commitment to advancing synthetic methodologies.

Career Highlights

Otto Phanstiel has worked with notable organizations including the University of Central Florida Research Foundation, Inc. and Mannkind Corporation. His tenure at these institutions allowed him to focus on research and development in the chemical synthesis domain, further solidifying his reputation as an innovative thinker and inventor.

Collaborations

Throughout his career, Otto has had the opportunity to collaborate with esteemed colleagues such as John J Freeman and Kelly Sullivan Kraft. These partnerships have contributed to an enriched exchange of ideas and creativity, ultimately leading to the development and success of his patented inventions.

Conclusion

Otto Phanstiel's journey as an inventor showcases his dedication to innovation in chemical synthesis. With 32 patents to his name, his contributions to activated fumarate intermediates and diketopiperazines reflect not only his expertise but also his commitment to advancing the field. As we continue to witness the impact of his work, it is clear that Otto Phanstiel will remain a significant figure in the world of inventions for years to come.

This text is generated by artificial intelligence and may not be accurate.